+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Diabetic Nephropathy - Pipeline Review, H2 2020

  • ID: 5146928
  • Drug Pipelines
  • August 2020
  • Region: Global
  • 269 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Aibios Co Ltd
  • Bayer AG
  • ChemoCentryx Inc
  • Gilead Sciences Inc
  • Merck & Co Inc
  • ProKidney LLC
  • MORE
Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy - Pipeline Review, H2 2020, provides an overview of the Diabetic Nephropathy (Metabolic Disorders) pipeline landscape.

Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels and smoking. This condition is managed by medication and dietary modification.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Diabetic Nephropathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews the key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 23, 11, 28 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.

Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Aibios Co Ltd
  • Bayer AG
  • ChemoCentryx Inc
  • Gilead Sciences Inc
  • Merck & Co Inc
  • ProKidney LLC
  • MORE
Introduction
  • Diabetic Nephropathy - Overview
  • Diabetic Nephropathy - Therapeutics Development
Diabetic Nephropathy - Therapeutics Assessment

Diabetic Nephropathy - Companies Involved in Therapeutics Development

Diabetic Nephropathy - Drug Profiles

Diabetic Nephropathy - Dormant Projects
  • Diabetic Nephropathy - Discontinued Products
  • Diabetic Nephropathy - Product Development Milestones
Appendix

List of Tables
  • Number of Products under Development for Diabetic Nephropathy, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Companies, H2 2020 (Contd..2), H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..2), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..3), H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Target, H2 2020 (Contd..1), H2 2020
  • Number of Products by Stage and Target, H2 2020 (Contd..2), H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020 (Contd..1), H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020 (Contd..2), H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Diabetic Nephropathy - Pipeline by Aerpio Pharmaceuticals Inc, H2 2020
  • Diabetic Nephropathy - Pipeline by Aibios Co Ltd, H2 2020
  • Diabetic Nephropathy - Pipeline by Algomedix Inc, H2 2020
  • Diabetic Nephropathy - Pipeline by Antisense Therapeutics Ltd, H2 2020
  • Diabetic Nephropathy - Pipeline by APT Therapeutics Inc, H2 2020
  • Diabetic Nephropathy - Dormant Projects, H2 2020
  • Diabetic Nephropathy - Dormant Projects, H2 2020 (Contd..1), H2 2020
  • Diabetic Nephropathy - Dormant Projects, H2 2020 (Contd..2), H2 2020
  • Diabetic Nephropathy - Dormant Projects, H2 2020 (Contd..3), H2 2020
  • Diabetic Nephropathy - Dormant Projects, H2 2020 (Contd..4), H2 2020
  • Diabetic Nephropathy - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Diabetic Nephropathy, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • Aerpio Pharmaceuticals Inc
  • Aibios Co Ltd
  • Algomedix Inc
  • Antisense Therapeutics Ltd
  • APT Therapeutics Inc
  • AptaBio Therapeutics Inc
  • Araim Pharmaceuticals Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Bayer AG
  • Betagenon AB
  • Bird Rock Bio Inc
  • BLR Bio LLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co
  • CCRP Therapeutics GmbH
  • Cellmid Ltd
  • Certa Therapeutics Pty Ltd
  • ChemoCentryx Inc
  • CSL Ltd
  • cStem Regeneration Pharmaceutical Co Ltd
  • Curacle Co Ltd
  • Cyclerion Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Dimerix Ltd
  • Future Medicine Co Ltd
  • GenKyoTex SA
  • Gilead Sciences Inc
  • Glycadia Inc
  • GNI Group Ltd
  • Goldfinch Bio Inc
  • Guangzhou Magpie Pharmaceutical Co Ltd
  • Guangzhou Nanxin Pharmaceutical Co Ltd
  • Inspyr Therapeutics Inc
  • Johnson & Johnson
  • MediPost Co Ltd
  • Merck & Co Inc
  • Mesoblast Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Novartis AG
  • Novo Nordisk AS
  • Noxxon Pharma AG
  • Orbsen Therapeutics Ltd
  • PhytoHealth Corp
  • ProKidney LLC
  • Reata Pharmaceuticals Inc
  • Redx Pharma Plc
  • Scohia Pharma Inc
  • Serodus ASA
  • siRNAgen Therapeutics Corp
  • Sulfateq BV
  • Teijin Pharma Ltd
  • Twoxar Inc
  • Vidasym Inc
  • ZyVersa Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll